文献速递临床试验与 GCP

数字化眩晕治疗:前庭性眩晕患者确证性随机对照试验的研究方案

Digital vertigo therapy: study protocol for a confirmatory randomized controlled trial in patients with vestibular vertigo.
PubMed 文献 · Trials · 2025-06-02

本研究为随机、组对照、单盲临床试验,评估前庭健康应用程序(VH-90-D DiGA)对前庭性眩晕患者的临床疗效与安全性。试验组接受数字化治疗(约每日15分钟,持续90天),对照组接受德国法定医疗计划规定的物理治疗(通常为6次、每次20分钟的现场物理治疗)。主要结局为眩晕强度(VSS-sf-VER量表,0-32分)从基线至第12周的变化组间差异,样本量含脱落共2×100例。

要点

  • 试验组接受数字化治疗约每日15分钟持续90天,对照组接受德国法定医疗计划物理治疗(通常6次、每次20分钟现场物理治疗)。
  • 主要结局为VSS-sf-VER量表(0-32分)从基线至第12周评分变化的组间差异,评估在第2、6、12周进行。
  • 样本量含脱落共2×100例;预期数字化治疗在效应量上统计学优于物理治疗。

核心结论

  • 本试验方案为确证性随机对照试验(GEVE II),旨在研究数字化眩晕治疗的有效性与安全性。
  • 预期数字化治疗在效应量上统计学优于物理治疗。

研究设计与样本

  • 随机、组对照、单盲临床试验,患者随机分配至两个治疗组,按预先确定的顺序检验终点。
  • 试验组接受数字化治疗(VH-90-D DiGA,约每日15分钟,持续90天),对照组接受德国法定医疗计划规定的物理治疗(通常为6次、每次20分钟现场物理治疗)。
  • 样本量含脱落共2×100例。

主要发现

  • 主要结局为采用德语版眩晕症状量表简版VSS-sf-VER(0-32分)测量的眩晕强度,评估在第2、6、12周进行。
  • 主要结局通过测量VSS-sf评分从基线至第12周变化的组间差异来确定。

关键数值与推荐

  • VSS-sf-VER量表评分范围为0-32分。
  • 样本量含脱落共2×100例。
  • 评估时间点为第2、6、12周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vestibular vertigo is one of the leading causes of disability. The clinical standard of care for vestibular vertigo includes physical activity producing central vestibular compensation (CVC). Home exercises are considered an integral part of physical therapy. However, a reliable solution is still needed to support the regular and correct execution of home exercises. For this purpose, VH-90-D DiGA was developed, which is a digital therapeutic (DTx) for multimodular in-home therapeutic training. OBJECTIVE: The purpose of this study is to assess the clinical efficacy and safety of a vestibular health app for patients with vestibular vertigo. METHODS: A randomized group-controlled single-blinded clinical trial (RCT) has been designed. Patients will be randomly assigned to one of two treatment groups and the endpoints examined in a pre-determined order. The experimental group receives the DTx (around 15 min/daily for 90 days), and the control receives physiotherapy according to the German statutory health care plan (usually 6 × 20 min of live physiotherapy). The primary outcome will be vertigo intensity measured using the German version of the validated Vertigo Symptom Scale-short form VSS-sf-VER (0-32 score points). Evaluation is performed after 2, 6, and 12 weeks. Primary outcomes are determined by measuring the group differences of the VSS-sf-score point changes from baseline to week twelve. Including dropouts, the sample size has been determined to be 2 × 100. EXPECTED RESULTS: It is expected that therapy with the DTx will be statistically superior to physiotherapy in terms of effect size. DISCUSSION: This trial protocol marks a confirmatory RCT (GEVE II) to investigate the efficacy and safety of a digital vertigo treatment. The planned RCT is based on a series of primary and secondary efficacy variables. Examination of the endpoints in a pre-determined order ensures the rigor of confirmatory statistics and addresses the challenge of multiplicity. This sequential testing continues until significance is achieved. However, if a specific variable fails to reach significance, subsequent variables will be explored solely on a descriptive basis. TRIAL REGISTRATION: German National Registry of Clinical Studies (DRKS00028026), a WHO ICRTP registry. Registered on December 12, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wirth M, Pieper J, Heller U, et al. Digital vertigo therapy: study protocol for a confirmatory randomized controlled trial in patients with vestibular vertigo. Trials. 2025. PMID: 40452052. doi:10.1186/s13063-025-08775-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。